ImmuneOnco affiliate ImmuneCare attracts RMB 50 million in capital increase for 15.83% stake

PUBT · 1d ago
ImmuneOnco affiliate ImmuneCare attracts RMB 50 million in capital increase for 15.83% stake
  • ImmuneOnco agreed a RMB 50 million capital increase in non-wholly owned unit ImmuneCare Biopharmaceutical (Shanghai) on Aug. 6, 2026.
  • External investors will subscribe for RMB 465,000 of enlarged registered capital, taking a combined 15.83% stake.
  • ImmuneOnco will convert a RMB 15.86 million shareholder loan into RMB 147,498 of enlarged registered capital at the same price.
  • Post-transaction ownership: ImmuneOnco 68.34%; employee platform Jiaxing Changxin 15.83%; investors 15.83%.
  • ImmuneCare develops drugs for metabolic and rare diseases; proceeds aimed at strengthening funding for ongoing R&D.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneonco Biopharmaceuticals (Shanghai) Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260807-12276425), on August 06, 2026, and is solely responsible for the information contained therein.